<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(3)</volume><submitter>Garcia-Arredondo A</submitter><pubmed_abstract>The European continent is inhabited by medically important venomous Viperinae snakes. Vipera ammodytes, Vipera berus, and Vipera aspis cause the greatest public health problems in Europe, but there are other equally significant snakes in specific regions of the continent. Immunotherapy is indicated for patients with systemic envenoming, of which there are approximately 4000 annual cases in Europe, and was suggested as an indication for young children and pregnant women, even if they do not have systemic symptoms. In the present study, the safety and venom-neutralizing efficacy of Inoserp Europe-a new F(ab')₂ polyvalent antivenom, designed to treat envenoming by snakes in the Eurasian region-were evaluated. In accordance with World Health Organization recommendations, several quality contro</pubmed_abstract><journal>Toxins</journal><pagination>E149</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6468668</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Preclinical Assessment of a New Polyvalent Antivenom (Inoserp Europe) against Several Species of the Subfamily Viperinae.</pubmed_title><pmcid>PMC6468668</pmcid><pubmed_authors>Saldivar A</pubmed_authors><pubmed_authors>Garcia-Arredondo A</pubmed_authors><pubmed_authors>Martinez M</pubmed_authors><pubmed_authors>Soria R</pubmed_authors><pubmed_authors>Calderon A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Preclinical Assessment of a New Polyvalent Antivenom (Inoserp Europe) against Several Species of the Subfamily Viperinae.</name><description>The European continent is inhabited by medically important venomous Viperinae snakes. Vipera ammodytes, Vipera berus, and Vipera aspis cause the greatest public health problems in Europe, but there are other equally significant snakes in specific regions of the continent. Immunotherapy is indicated for patients with systemic envenoming, of which there are approximately 4000 annual cases in Europe, and was suggested as an indication for young children and pregnant women, even if they do not have systemic symptoms. In the present study, the safety and venom-neutralizing efficacy of Inoserp Europe-a new F(ab')₂ polyvalent antivenom, designed to treat envenoming by snakes in the Eurasian region-were evaluated. In accordance with World Health Organization recommendations, several quality contro</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Mar</publication><modification>2025-04-19T21:54:15.729Z</modification><creation>2019-06-06T22:45:27Z</creation></dates><accession>S-EPMC6468668</accession><cross_references><pubmed>30841582</pubmed><doi>10.3390/toxins11030149</doi></cross_references></HashMap>